Wave Life Sciences Ltd. (WVE) — SEC Filings
Wave Life Sciences Ltd. (WVE) — 50 SEC filings. Latest: 10-Q (Apr 28, 2026). Includes 27 8-K, 7 10-Q, 4 SC 13G/A.
View Wave Life Sciences Ltd. on SEC EDGAR
Overview
Wave Life Sciences Ltd. (WVE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 15, 2026: Wave Life Sciences Ltd. filed a Definitive Additional Materials (DEFA14A) on April 15, 2026. This filing is related to proxy materials and does not contain specific financial figures or operational updates within the provided text. The filing is primarily procedural, concerning the solicitation of p
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bullish, 46 neutral, 2 mixed. The dominant filing sentiment for Wave Life Sciences Ltd. is neutral.
Filing Type Overview
Wave Life Sciences Ltd. (WVE) has filed 1 4, 7 10-Q, 1 DEFA14A, 27 8-K, 1 8-K/A, 2 DEF 14A, 2 10-K/A, 2 10-K, 4 SC 13G/A, 2 SC 13G, 1 SC 13D/A with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of WVE's 35 recent filings, 2 were flagged as high-risk, 11 as medium-risk, and 22 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $7.608M |
| Net Income | -$53.852M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $196.218M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Singapore
- Cambridge, Massachusetts
- GregoryVerdine
- AikNaTan
- HeidiWagner
- Peter Kolchinsky
- Dr. Paul Bolno
- Mr. David Epstein
- Paul B. Bolno
- Christopher Francis
Industry Context
The RNA therapeutics sector is a rapidly evolving and highly competitive field, characterized by significant R&D investment and a focus on novel drug delivery and targeting mechanisms. Companies like Wave Life Sciences are navigating a landscape with both immense potential for treating genetic diseases and substantial scientific and regulatory hurdles. Key trends include the development of more precise RNA-modulating drugs and the expansion into new therapeutic areas.
Top Tags
disclosure (6) · financial-reporting (6) · 8-K (5) · regulatory-filing (5) · financials (5) · Biotechnology (4) · 8-k (4) · 10-Q (4) · sec-filing (4) · biotech (4)
Executive Compensation
From the most recent DEF 14A filing (Jun 23, 2025):
- Not Disclosed — Principal Executive Officer: $0
- Not Disclosed — Principal Financial Officer: $0
- Not Disclosed — Other Named Executive Officers: $0
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (9 months ended Sep 30, 2025) | $151.199M | Increased from $126.261M in 2024, indicating higher operational costs. |
| Cash and Cash Equivalents (Sep 30, 2025) | $196.218M | Decreased from $302.078M at Dec 31, 2024, reflecting significant cash burn. |
| Revenue (3 months ended Sep 30, 2025) | $7.608M | Significant turnaround from negative $7.676M in the same period of 2024. |
| Research and Development Expenses (9 months ended Sep 30, 2025) | $129.965M | Increased from $115.037M in 2024, showing continued investment in pipeline. |
| Net Loss (3 months ended Sep 30, 2025) | $53.852M | Improved from $61.780M in the same period of 2024. |
| Outstanding Ordinary Shares (Nov 7, 2025) | 167,181,784 | Indicates potential dilution from previous equity programs. |
| SEC File Number | 001-37627 | Identifies the company's filing with the SEC. |
| Fiscal Year End | 1231 | Indicates the end of the company's financial reporting year. |
| Net Loss | $48.5M | Decreased from $57.2M in Q2 2024, showing improved financial management. |
| Revenue | $10.2M | Increased 20% from $8.5M in Q2 2024, primarily from collaboration agreements. |
| R&D Expenses | $35.1M | Decreased from $42.3M in Q2 2024, reflecting strategic pipeline adjustments. |
| Cash and Equivalents | $150.3M | Available capital as of June 30, 2025, to fund operations. |
| Accumulated Deficit | $1.2B | As of June 30, 2025, highlighting historical unprofitability. |
| Filing Date | 2025-06-23 | Date the DEF 14A was filed with the SEC. |
| SIC Code | 2834 | Standard Industrial Classification for Pharmaceutical Preparations, indicating the company's industry. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Wave Life Sciences Ltd. (WVE)?
Wave Life Sciences Ltd. has 50 recent SEC filings from Feb 2024 to Apr 2026, including 27 8-K, 7 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of WVE filings?
Across 50 filings, the sentiment breakdown is: 2 bullish, 46 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Wave Life Sciences Ltd. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Wave Life Sciences Ltd. (WVE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Wave Life Sciences Ltd.?
Key financial highlights from Wave Life Sciences Ltd.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for WVE?
The investment thesis for WVE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Wave Life Sciences Ltd.?
Key executives identified across Wave Life Sciences Ltd.'s filings include Singapore, Cambridge, Massachusetts, GregoryVerdine, AikNaTan, HeidiWagner and 5 others.
What are the main risk factors for Wave Life Sciences Ltd. stock?
Of WVE's 35 assessed filings, 2 were flagged high-risk, 11 medium-risk, and 22 low-risk.
What are recent predictions and forward guidance from Wave Life Sciences Ltd.?
Forward guidance and predictions for Wave Life Sciences Ltd. are extracted from SEC filings as they are enriched.